Drug metabolic activity as a selection factor for pluripotent stem cell-derived hepatic progenitor cells

Prog Mol Biol Transl Sci. 2023:199:155-178. doi: 10.1016/bs.pmbts.2023.02.009. Epub 2023 Jul 26.

Abstract

As a metabolic organ, the liver plays a variety of roles, including detoxification. It has been difficult to obtain stable supplies of hepatocytes for transplantation and for accurate hepatotoxicity determination in drug discovery research. Human pluripotent stem cells, capable of unlimited self-renewal, may be a promising source of hepatocytes. In order to develop a stable supply of embryonic stem cell (ESC)-derived hepatocytes, we have purified human ESC-derived hepatic progenitor cells with exposure to cytocidal puromycin by using their ability to metabolize drugs. Hepatic progenitor cells stably proliferated at least 220-fold over 120 days, maintaining hepatic progenitor cell-like properties. High drug-metabolizing hepatic progenitor cells can be matured into liver cells by suppressing hepatic proliferative signals. The method we developed enables the isolation and proliferation of functional hepatic progenitors from human ESCs, thereby providing a stable supply of high-quality cell resources at high efficiency. Cells produced by this method may facilitate cell therapy for hepatic diseases and reliable drug discovery research.

Keywords: Cytochrome P450; Hepatic progenitor cell; Hepatocyte; Liver regeneration; Pluripotent stem cell.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Drug Discovery
  • Embryonic Stem Cells
  • Eye Diseases, Hereditary*
  • Humans
  • Liver
  • Pluripotent Stem Cells*